The genetic alterations of appendiceal carcinomas have not been reported in detail. We studied the clinicopathological factors and genetic alterations including microsatellite instability, p53 overexpression, and mutations of the K-ras proto-oncogene of 30 appendiceal adenocarcinomas, consisting of 23 mucinous and 7 nonmucinous carcinomas. Sixteen (70%) mucinous carcinomas presented with pseudomyxoma peritonei, but 6 of 7 (86%) nonmucinous carcinomas presented with appendicitis (P ‫؍‬ .002). All carcinomas were microsatellite stable, and p53 overexpression was present in only 1 of 30 (3%) carcinomas. K-ras mutation was present in 11 of 20 (55%) carcinomas, including 8 of 16 (50%) mucinous and 3 of 4 (75%) nonmucinous carcinomas. The mean survival of patients with mucinous carcinomas was 26 ؎ 19 months compared with 13 ؎ 9 months for patients with nonmucinous carcinomas (P ‫؍‬ .0002). Our findings suggest that mucinous and nonmucinous carcinomas of appendix have similar genetic alterations, but different clinical presentation and prognosis. KEY WORDS: Adenocarcinoma, Appendix, K-ras, Microsatellite instability, p53.
Appendiceal carcinoma is an uncommon malignancy of the gastrointestinal tract with a prevalence ranging from 0.2 to 0.3% of appendectomy specimens (1, 2) . Most appendiceal carcinomas arise from an adenomatous polyp or serrated adenoma (3) (4) (5) and present clinically with pseudomyxoma peritonei.
Most colorectal cancers develop from adenomatous polyps, and morphological and genetic progression in an adenoma-adenocarcinoma sequence and in hereditary colorectal cancer syndromes are well described (6 -9) . The majority of colorectal cancers have truncating mutations or deletions of the adenomatous polyposis coli (APC) gene on chromosome 5q or mutations of the ␤-catenin gene. Point mutations of the K-ras protooncogene and mutations and/or deletions of the p53 gene on chromosome 17p are also common. In a second pathway to colorectal neoplasia, microsatellite instability (MSI; also termed DNA replication errors and ubiquitous somatic mutations) is caused by mutations in a nucleotide mismatch repair gene, including hMSH2, hMLH1, PMS1, PMS2, and GTBP (6 -9) . MSI is characterized by additions and deletions of nucleotides in numerous repeated nucleotide sequences (microsatellites). MSI is frequent in the right-sided colon carcinomas and mucinous colorectal carcinomas (6 -9) .
The genetic alterations in appendiceal carcinoma have not been reported in detail. We therefore studied MSI, p53 overexpression, and K-ras mutations in appendiceal carcinomas and compared these genetic alterations with the clinicopathologic findings.
MATERIALS AND METHODS

Case Material
A computer search of MD Anderson Cancer Center surgical pathology diagnoses from 1995 through 2000 was performed. Primary appendiceal carcinomas were identified using the World Health Organization classification of appendiceal carcinomas (10) . There were 30 patients with primary appendiceal carcinomas and available paraffin-embedded blocks. Neuroendocrine tumors were excluded. The patient records and histopathological findings were reviewed. Primary site in the appendix was verified by histology in 18 cases and by report of an outside institution in the remaining 12 cases. Familial history of appendiceal or colorectal carcinoma was not present in any patient.
DNA Preparation
Genomic DNA was extracted separately from appendiceal carcinoma and control nonlesional appendiceal or colorectal tissue by microdissection from paraffin-embedded blocks, as described in previous studies (11) .
Microsatellite Markers and Polymerase Chain Reaction Amplification
Fluorescent-labeled polymerase chain reaction (PCR) amplification was performed using the markers recommended by the National Cancer Institute workshop (12) . The fluorescent dye-labeled and unlabeled primers were obtained (Life Technologies, Gaithersburg, MD). The 5' oligonucleotide was end labeled with 6-FAM (BAT-25, D17S250), TET (BAT-26, D2S123), or HEX (D5S346) fluorescent dye. PCR was performed with 40 ng of DNA in reaction mix consisting of 1ϫ GeneAmp PCR Gold buffer (Applied Biosystems, Foster City, CA), 2.5 mM of MgCl 2 , 200 M of dNTPs, 0.83 M of each primer, and 2 U of AmpliTaq Gold DNA polymerase (Applied Biosystems) in a final volume of 15 L. PCR was performed using a GENE-AMP PCR system 9700 (Applied Biosystems) with the following conditions: 95°C for 7 minutes; 3 cycles at 94°C for 1 minute, 58°C for 30 seconds, and 72°C for 45 seconds; 42 cycles at 93°C for 45 seconds, 54°C for 30 seconds, and 72°C for 40 seconds; and final extension at 72°C for 10 minutes. A 0.25-L aliquot of each fluorescent-labeled PCR product was analyzed on an ABI 310 Genetic Analyzer using GeneScan Analysis software (Applied Biosystems). Each sample included GeneScan 500 (TAMARA) size standard for accurate size calling.
Microsatellite Instability
The presence of MSI was determined from the PCR amplifications of the two mononucleotide markers (BAT-25 and BAT-26) and three dinucleotide markers (D2S123, D5S346, D17S250; 12). Mononucleotide markers (BAT-25 and BAT-26) were used to assess MSI in specimens without nonlesional DNA. Specimens with high levels of MSI (MSI-H) were defined by shifts of bands as compared with the control DNA in Ն40% of evaluable markers, and low levels of MSI (MSI-L), by shifts in Ͻ40% of evaluable microsatellite markers.
Immunohistochemistry for p53 Overexpression
Immunohistochemistry with mouse monoclonal antibody D07 (1:250 dilution) and standard techniques including antigen retrieval was used to determine p53 gene product overexpression as in our previous studies (13) . Overexpression of p53 was considered to be present when Ͼ50% of the nuclei of tumor cells stained by immunohistochemistry.
DNA Sequencing of K-ras
Exon 1 of K-ras gene was amplified by PCR as previously described (14) . PCR reaction was performed in a 50-L volume using PCR Master (Roche Diagnostics Corporation, Indianapolis, IN) and 1 M of 5' and 3' primers, with initial denaturation at 95°C for 5 minutes; 40 cycles at 94°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minutes; and a final extension cycle at 72°C for 10 minutes. The PCR products were treated with shrimp alkaline phosphatase and exonuclease I (United States Biochemical, Cleveland, OH) and sequenced using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) with internal primer. The sequence reactions were run on an Applied Biosystems 3700 Genetic Analyzer (Applied Biosystems). The data were collected and analyzed using Applied Biosystems sequencing analysis software (Applied Biosystems), according to the manufacturer's protocols. Each mutation was verified by sequencing in both directions.
Clinicopathological Correlation
The K-ras mutation status was compared with the clinical and pathologic parameters, including age and sex of patients; histological type, grade, and stage of carcinoma; presence of pseudomyxoma peritonei; association with appendiceal adenoma; rupture of appendix; and treatment and follow-up status.
Statistical Analysis
The clinicopathological associations were compared with histological type of carcinomas and K-ras mutation status using chi-square, Fisher's exact, or nonpaired t test. The overall survival time and disease-free survival of patients with mucinous and nonmucinous carcinomas was compared by the Kaplan and Meier method (15) by using SPSS for Windows software (SPSS Inc., Chicago, IL).
RESULTS
Clinicopathologic Factors
The clinicopathologic findings are summarized in Table 1 . Twenty-three of 30 patients (77%) had a mucinous adenocarcinoma, including 22 with a low-grade mucinous adenocarcinoma ( Fig. 1 ) and 1 with mucinous adenocarcinoma with focal signetring cells comprising Ͻ50% of the tumor. Seven (23%) patients had nonmucinous gland-forming adenocarcinoma (Fig. 2) , including one with focal signet ring cell morphology (Fig. 3) . Six of 7 (86%) nonmucinous carcinomas were moderate or poorly differentiated, but all 23 mucinous carcinomas were well differentiated (P ϭ .00001; Table 1 ).
Patients with mucinous and nonmucinous carcinomas had different clinical presentation and sites of metastatic disease. Sixteen of 23 (70%) mucinous carcinomas presented with pseudomyxoma peritonei, but 6 of 7 (86%) nonmucinous carcinomas presented with appendicitis (P ϭ .002; Table 1 ). Similarly, omental metastases were present in 16 of 23 (62%) mucinous carcinomas, but none of 7 nonmucinous carcinomas (P ϭ .002). In contrast, liver or lung metastasis was present in 3 of 7 (43%) nonmucinous carcinomas, but in none of 17 mucinous carcinomas (P ϭ .01).
Patients with mucinous carcinoma had a better overall survival and disease-free survival. The mean overall survival of patients with mucinous carcinomas was 26 Ϯ 19 months, compared with 13 Ϯ 9 months for nonmucinous carcinomas ( Fig. 4A ; P ϭ .0002). The mean disease-free survival of patients with mucinous carcinomas was 18 Ϯ 3 months, compared with 7 Ϯ 4 months for nonmucinous carcinomas ( Fig. 4B ; P ϭ .04).
Genetic Alterations
Allelic shift was present in none of 30 carcinomas by mononucleotide markers (BAT-25 or BAT-26), nor in any of 19 carcinomas by dinucleotide markers (D2S123, D5S346, and D17S250). Thus, all carcinomas were classified as microsatellite stable.
p53 overexpression was present in only one moderately differentiated nonmucinous adenocarcinoma. K-ras mutations were present in 11 of 20 (55%) carcinomas. K-ras mutations were present in codon 12 of the K-ras gene in 9 of 20 (45%) carcinomas and in codon 13 in two of 20 (10%) carcinomas (Fig.  5) . The most frequent mutation was substitution of aspartic acid for glycine caused by G to A transition at codon 12 (GGT to GAT), which was present in 7 carcinomas. Other mutations were substitution of valine for glycine at codon 12 caused by G to T transversion in two carcinomas (GGT to GTT), and substitution of aspartic acid for glycine at codon 13 caused by G to A transition in two carcinomas (GGC to GAC). K-ras mutation was present in 8 of 16 (50%) mucinous carcinomas and in 3 of 4 (75%) nonmucinous carcinomas. There was no significant association of K-ras mutation with the clinicopathological characteristics of the tumor or patient (Table 2).
DISCUSSION
In this study, mucinous and nonmucinous carcinomas of the appendix had different clinical presentation and survival, but both subtypes of carcinomas lacked MSI or p53 overexpression and had frequent K-ras mutations. In contrast, colorectal carcinomas have frequent p53 overexpression, and right-sided colon carcinomas and/or mucinous histological type of colon carcinomas frequently have high levels of MSI (6 -9) . The frequency of K-ras mutation is similar in appendiceal and colorectal carcinomas, but the molecular pathogenesis differs.
K-ras mutation was present in 55% of appendiceal carcinomas in our study. In addition, K-ras mutations were frequent in mucinous and nonmucinous carcinomas in our study. Similarly, previous studies have also reported frequent K-ras mutations in appendiceal tumors associated with pseudomyxoma peritonei (16, 17) . In contrast, appendiceal carcinoid tumors, including those with mucinous-goblet cell differentiation, lack K-ras mutations (18) .
p53 overexpression was infrequent, as it was present in only one carcinoma in our study. This is corroborated by lack of allelic loss of 17p, the chromosomal location of the p53 gene in tumors associated with pseudomyxoma peritonei in a previous study (17) . Similarly, appendiceal carcinoid tumors have infrequent p53 gene mutations (19, 20) .
In our study, all the carcinomas had microsatellite stable genotype. In contrast, occasional allelic shift in a few appendiceal tumors with pseudomyxoma peritonei has been reported in a previous study (17) , and colorectal cancer with mucinous histology has high levels of MSI.
Most of the appendiceal carcinomas were associated with an appendiceal adenoma and/or rupture of appendix. An adenoma-carcinoma sequence exists in the appendix that is similar to the one described in the colorectum (3) (4) (5) . This is further corroborated by the presence of occasional appendiceal carcinomas in patients with familial adenomatous polyposis syndrome (21, 22) . In this study, the frequency of appendiceal adenomas was similar in both mucinous and nonmucinous types. The prevalence of adenoma in our study is likely an underestimate because of extensive replacement of adenoma by carcinoma; undersampling of adjacent, grossly normal appendiceal tissue; or unavailability of slides from source institutions for review.
The clinical presentation of appendiceal tumors differs by the histological type of cancer. Most patients with mucinous adenocarcinomas presented with pseudomyxoma peritonei. On the other hand, most nonmucinous carcinomas presented with appendicitis or acute abdomen. The origin and histological classification of pseudomyxoma peritonei is controversial (16, 17, (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) . Recent studies suggest that most cases of pseudomyxoma peritonei are caused by appendiceal mucinous tumors (17, 23) . Ronnett et al. (24) have classified patients with pseudomyxoma peritonei into two categories: disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Disseminated peritoneal adenomucinosis, also referred to by others (39) as dissecting mucin containing atypical epithelium, is characterized by peritoneal lesions composed of abundant extracellular mucin containing scant simple to focally proliferative mucinous epithelium with little cytological atypia or mitotic activity. In contrast, peritoneal mucinous carcinomatosis is characterized by peritoneal lesions composed of more abundant mucinous epithelium with the architectural and cytological features of carcinoma. The clinical course of adenomucinosis is protracted (for many years), with a good response to debulking and other modalities of treatment; death is usually due to complications of treatment (38) . On the other hand, prognosis of adenocarcinomatosis is generally worse, with shorter survival (40) . However, some patients show histological progression from one surgery to the next and die of their disease despite better histology (24, 40) . In our study, the mucinous carcinomas either showed invasion or had dysplastic epithelium, and most of our specimens were from a second operation. Our mucinous carcinomas would be classified as peritoneal mucinous carcinomatosis according to criteria used by Ronnett et al. (24) .
The survival was also dependent on the histological type of carcinoma, although only four patients died of disease in our series, with limited follow-up, including three with nonmucinous carcinomas and one with focal signet-ring differentiation. This sug- gests that the nonmucinous carcinomas or signetring cell carcinomas are aggressive neoplasms in contrast to mucinous carcinomas. Better prognosis of mucinous carcinomas has been reported (41, 42) .
Limited data are available from the literature on molecular genetic alterations in mucinous appendiceal carcinomas (10) . K-ras mutations and loss of chromosomal arms including 3p, 5q22, 6q, 17p13, and 18q21 have been reported in mucinous carcinomas to support clonality of separate foci but were not correlated with a clinical outcome (16, 17, 43, 44) . In contrast, molecular genetic alterations and clinical behavior of nonmucinous appendiceal carcinomas have not been reported in the literature. Cytogenetic analysis, comparative genomic hybridization, genome-wide allelotyping, and microarray technology can help in further molecular characterization of these carcinomas. Xenografts or tissue culture can help in getting abundant amount of enriched tumor samples for these studies, which is a major problem for mucinous carcinomas.
In summary, genetic alterations in appendiceal carcinomas differ from colorectal carcinomas and consist of frequent K-ras proto-oncogene mutation but not alterations of p53 tumor suppressor gene or MSI genotype. The clinical presentation and overall survival differs between mucinous and nonmucinous carcinomas. Data in first three columns are n (%) unless otherwise indicated. ANED, alive with no evidence of disease; AWD, alive with disease; LFU, lost to follow-up; F, female; M, male; NA, not applicable; NS, not significant.
